These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31184501)

  • 1. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
    Grunenberg A; Buske C
    Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Emerging Treatments for Waldenström Macroglobulinemia.
    Grimont CN; Castillo Almeida NE; Gertz MA
    Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
    Izutsu K; Kato H; Sekiguchi N; Fujisaki T; Kawakita T; Obara N; Matsue K; Nishimoto M; Hatayama T; Inagaki M; Fujikawa E
    Int J Hematol; 2024 Jul; 120(1):80-90. PubMed ID: 38597986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
    Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
    N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
    Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
    Treon SP; Xu L; Hunter Z
    N Engl J Med; 2015 Aug; 373(6):584-6. PubMed ID: 26244327
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
    Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
    D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
    J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
    Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
    [No Abstract]   [Full Text] [Related]  

  • 13. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
    Ailawadhi S; Paulus A; Chanan-Khan A
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
    Grunenberg A; Buske C
    Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.
    Migkou M; Fotiou D; Gavriatopoulou M; Dimopoulos MA
    Expert Opin Drug Saf; 2021 Sep; 20(9):987-995. PubMed ID: 34137347
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
    Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
    Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 20. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.